

September 7, 2021



## iBio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

BRYAN, Texas, Sept. 07, 2021 (GLOBE NEWSWIRE) -- [iBio, Inc.](https://www.ibioinc.com) (NYSEA:IBIO) ("iBio" or the "Company"), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based **FastPharming** Manufacturing System<sup>®</sup>, today announced that it will participate in the H.C. Wainwright 23<sup>rd</sup> Annual Global Investment Conference, to be held virtually September 13-15, 2021.

iBio's pre-recorded presentation will be available on demand during the event for all registered attendees. Beginning on Monday, September 13, 2021, the presentation will also be available on the Company's website at [www.ibioinc.com](https://www.ibioinc.com) under "News & Events" in the Investors section.

### About iBio, Inc.

iBio is a developer of next-generation biopharmaceuticals and a pioneer in sustainable, plant-based biologics manufacturing. Its **FastPharming** System<sup>®</sup> combines vertical farming, automated hydroponics, and novel glycosylation technologies to rapidly deliver high-quality monoclonal antibodies, vaccines, biinks and other proteins. iBio is developing proprietary biopharmaceuticals for the treatment of cancers, as well as fibrotic and infectious diseases. The Company's subsidiary, iBio CDMO LLC, provides **FastPharming** Contract Development and Manufacturing Services along with **Glycaneering**<sup>™</sup> Development Services for advanced recombinant protein design. For more information, visit [www.ibioinc.com](https://www.ibioinc.com).

### Contact:

Stephen Kilmer  
iBio, Inc.  
Investor Relations  
(646) 274-3580  
[skilmer@ibioinc.com](mailto:skilmer@ibioinc.com)



Source: iBio, Inc.